{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03168438",
      "OrgStudyIdInfo": {
        "OrgStudyId": "208470"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "ADP-0011-008",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Adaptimmune Therapeutics"
          },
          {
            "SecondaryId": "KEYNOTE-487",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Merck Sharp and Dohme Corp."
          }
        ]
      },
      "Organization": {
        "OrgFullName": "GlaxoSmithKline",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma",
      "OfficialTitle": "Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Terminated",
      "WhyStopped": "The study was terminated following an internal review of the company's research and development portfolio",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 18, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 13, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 5, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "May 24, 2017",
      "StudyFirstSubmitQCDate": "May 24, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 30, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "ResultsFirstSubmitDate": "November 9, 2021",
      "ResultsFirstSubmitQCDate": "November 9, 2021",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "January 11, 2022",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 9, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 11, 2022",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "GlaxoSmithKline",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Merck Sharp & Dohme Corp.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Neoplasms"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Relapsed and Refractory Multiple Myeloma",
          "T Cell Receptor",
          "Immuno-oncology",
          "NY-ESO-1",
          "Leukapheresis",
          "Adoptive TCR T-cell therapy",
          "Letetresgene autoleucel"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Arm 1: Letetresgene autoleucel (GSK3377794)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Letetresgene autoleucel",
                "Drug: Fludarabine",
                "Drug: Cyclophosphamide"
              ]
            }
          },
          {
            "ArmGroupLabel": "Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Letetresgene autoleucel with pembrolizumab",
                "Drug: Fludarabine",
                "Drug: Cyclophosphamide",
                "Drug: Pembrolizumab"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Letetresgene autoleucel",
            "InterventionDescription": "Letetresgene autoleucel (GSK3377794) as an IV infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm 1: Letetresgene autoleucel (GSK3377794)"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Letetresgene autoleucel with pembrolizumab",
            "InterventionDescription": "Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Fludarabine",
            "InterventionDescription": "Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm 1: Letetresgene autoleucel (GSK3377794)",
                "Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Cyclophosphamide",
            "InterventionDescription": "Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm 1: Letetresgene autoleucel (GSK3377794)",
                "Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Pembrolizumab",
            "InterventionDescription": "Pembrolizumab is available as an IV infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "PrimaryOutcomeDescription": "An AE is any untoward medical occurrence in a participant or clinical investigation participant who received a study treatment and the event need not necessarily have a causal relationship with study treatment. An SAE is any AE that results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability; is a congenital anomaly/birth defect; is clinically significant or requires intervention to prevent one of the outcomes listed before.",
            "PrimaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only",
            "PrimaryOutcomeDescription": "The following toxicities were considered to be treatment limiting toxicities: any >=Grade 4 AE; Grade 3 non-infectious pneumonitis and any other Grade 3 AE (excluding pneumonitis), that did not improve to Grade 2 within 7 days after onset despite medical management and supportive care. Exceptions included the following: Grade 3 or 4 leukopenia, lymphopenia, neutropenia, or febrile neutropenia; Grade 3 or 4 thrombocytopenia not associated with significant bleeding; Grade 3 anemia; Grade 4 cytokine release syndrome (CRS) or toxicities related to CRS that resolved to Grade <=2 within 7 days; other Grade 3 laboratory abnormality determined to be not clinically significant by the Investigator; Grade 3 or 4 fever and chills; Grade 3 or 4 hypoalbuminemia or abnormal electrolytes that responded to supplementation/correction; AE related to the cancer or its progression.",
            "PrimaryOutcomeTimeFrame": "Up to 3 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline",
            "PrimaryOutcomeDescription": "Blood samples were collected for the assessment of following clinical chemistry parameters: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, phosphate, sodium and calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.",
            "PrimaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline",
            "PrimaryOutcomeDescription": "Blood samples were collected for the assessment of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.",
            "PrimaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline",
            "PrimaryOutcomeDescription": "Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.",
            "PrimaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings",
            "PrimaryOutcomeDescription": "ECG was recorded using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.",
            "PrimaryOutcomeTimeFrame": "Up to 108 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Overall Response Rate",
            "SecondaryOutcomeDescription": "Overall response rate is defined as the percentage of participants with a best overall response (BOR) of confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) Response Criteria (2016); where, PR: >=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by >=90% or to <200 milligrams (mg) per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <= 5% plasma cells in bone marrow; or sCR: CR as defined by normal free light chain (FLC) ratio and absence of clonal cells by immunohistochemistry. Confidence intervals were calculated using the exact (Clopper-Pearson) method.",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Time to Response",
            "SecondaryOutcomeDescription": "Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Duration of Response",
            "SecondaryOutcomeDescription": "Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Progression-free Survival",
            "SecondaryOutcomeDescription": "Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of >=0.5 grams per deciliter (g/dL); Serum M-protein increase >=1 g/dL if the lowest M-component was >=5 g/dL; Urinary M-protein (absolute increase must be >=200 mg per 24 hours).",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Maximum Persistence (Cmax) of GSK3377794",
            "SecondaryOutcomeDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Time to Maximum Persistence",
            "SecondaryOutcomeDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.",
            "SecondaryOutcomeTimeFrame": "Up to 108 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])",
            "SecondaryOutcomeDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.",
            "SecondaryOutcomeTimeFrame": "Up to Day 28"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge >=18 years of age or older on the date of signing informed consent.\nHistologically confirmed diagnosis of secretory multiple myeloma with myeloma markers at levels defined in the protocol.\nDocumented diagnosis of relapsed and refractory multiple myeloma (RRMM) (at least 3 prior regimens and responsive to at least 1, and refractory to most recent prior therapies, which must have included one or more than one drug from each of the following drug classes: an immunomodulatory imide drug (IMiD), proteasome inhibitor, alkylator (unless the participant is ineligible or contraindicated to receive an alkylator), CD 38 monoclonal antibody, and glucocorticoid as separate lines or a combined line of therapy.- Left ventricular ejection fraction (LVEF) >= 50%. Lower LVEF (>= 40%) permissible if formal cardiologic evaluation reveals no evidence for clinically significant functional impairment.\nMeets protocol criteria for patients who have previously received checkpoint inhibitors or other immuno-oncology agents.\nECOG Performance Status 0 or 1.\nParticipant is HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 positive as determined by a designated central laboratory.\nParticipant has confirmed sufficient expression of NY-ESO-1 and/or LAGE-1a as determined by a designated central laboratory.\nIn the Investigator's opinion, the participant is fit for cell collection.\nParticipant has adequate organ function and cell counts as described in the protocol.\nParticipants previously treated with BCMA therapy (BCMA chimeric antigen receptor (CAR)-T, antibody-drug conjugate (ADC), or other type of BCMA-targeted therapy) must have progressed from this therapy prior to attending the Baseline visit prior to beginning lymphodepletion.\nContraception use by male and female participant meets protocol requirements.\n\nExclusion Criteria:\n\nHas only plasmacytomas, plasma cell leukemia, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), non-secretory myeloma or primarily amyloidosis.\nPreviously received anti- programmed death (PD)-1, anti-PD-ligand (L)1, or anti-PD-L2 inhibitor.\nPreviously participated in Merck pivotal trial NCT02576977: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab in Refractory or RRMM.\nHad a prior allogeneic stem cell transplant.\nHas ongoing toxicity from previous anticancer therapy.\nHad a major surgery within 4 weeks prior to enrollment.\nHas history of allergic reactions to fludarabine, cyclophosphamide or agents similar to fludarabine, cyclophosphamide or other agents used in the study.\nKnown history of myelodysplasia.\nCurrent active liver or biliary disease.\nKnown history of chronic active hepatitis or liver cirrhosis.\nParticipant has an active viral infection.\nHistory of severe immune disease, including non-infectious pneumonitis, requiring steroids or other immunosuppressive treatments.\nActive immune-mediated diseases.\nPrior or active demyelinating disease.\nEvidence or history of significant cardiac disease.\nEvidence or history of other significant, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease.\nParticipants with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, carcinoma in situ of the breast, treated superficial bladder cancer or prostate cancer, or in situ cervical cancers ) not in complete remission.\nKnown active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may be eligible.\nActive bacterial or systemic viral or fungal infections.\nPregnant or breastfeeding.\nCannot meet washout periods for prior radiotherapy, chemotherapy or other protocol-specified therapies.\nMore than 2 years have passed since the participant's last leukapheresis collection.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "GSK Clinical Trials",
            "OverallOfficialAffiliation": "GlaxoSmithKline",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "GSK Investigational Site",
            "LocationCity": "Duarte",
            "LocationState": "California",
            "LocationZip": "91010",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "GSK Investigational Site",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "GSK Investigational Site",
            "LocationCity": "Tampa",
            "LocationState": "Florida",
            "LocationZip": "33612-9497",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "GSK Investigational Site",
            "LocationCity": "Atlanta",
            "LocationState": "Georgia",
            "LocationZip": "30322",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "GSK Investigational Site",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21201",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes",
      "IPDSharingDescription": "IPD for this study will be made available via the Clinical Study Data Request site.",
      "IPDSharingInfoTypeList": {
        "IPDSharingInfoType": [
          "Study Protocol",
          "Statistical Analysis Plan (SAP)",
          "Informed Consent Form (ICF)",
          "Clinical Study Report (CSR)"
        ]
      },
      "IPDSharingTimeFrame": "IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.",
      "IPDSharingAccessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",
      "IPDSharingURL": "http://clinicalstudydatarequest.com"
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowPreAssignmentDetails": "A total of 127 participants were screened of which 6 participants were enrolled in the study. The study was terminated due to challenging screening and enrollment combined with a rapidly changing treatment landscape.",
      "FlowRecruitmentDetails": "This was a pilot study to assess safety and tolerability of genetically engineered New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (c259) T Cells Alone or in combination with pembrolizumab in participants with relapsed/refractory multiple myeloma. The study was conducted in the United States.",
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "GSK3377794",
            "FlowGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "GSK3377794+Pembrolizumab",
            "FlowGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "3"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "3"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "3"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "2"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            },
            "FlowDropWithdrawList": {
              "FlowDropWithdraw": [
                {
                  "FlowDropWithdrawType": "Long term follow-up declined, study terminated by sponsor",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "GSK3377794",
            "BaselineGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "GSK3377794+Pembrolizumab",
            "BaselineGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "3"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "3"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "6"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "Years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "66.0",
                              "BaselineMeasurementSpread": "11.27"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "64.3",
                              "BaselineMeasurementSpread": "2.52"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "65.2",
                              "BaselineMeasurementSpread": "7.36"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race/Ethnicity, Customized",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "OutcomeMeasureDescription": "An AE is any untoward medical occurrence in a participant or clinical investigation participant who received a study treatment and the event need not necessarily have a causal relationship with study treatment. An SAE is any AE that results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability; is a congenital anomaly/birth defect; is clinically significant or requires intervention to prevent one of the outcomes listed before.",
            "OutcomeMeasurePopulationDescription": "Intent-To-Treat (ITT) Population comprised of all participants who underwent leukapheresis",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Any AE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Any SAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only",
            "OutcomeMeasureDescription": "The following toxicities were considered to be treatment limiting toxicities: any >=Grade 4 AE; Grade 3 non-infectious pneumonitis and any other Grade 3 AE (excluding pneumonitis), that did not improve to Grade 2 within 7 days after onset despite medical management and supportive care. Exceptions included the following: Grade 3 or 4 leukopenia, lymphopenia, neutropenia, or febrile neutropenia; Grade 3 or 4 thrombocytopenia not associated with significant bleeding; Grade 3 anemia; Grade 4 cytokine release syndrome (CRS) or toxicities related to CRS that resolved to Grade <=2 within 7 days; other Grade 3 laboratory abnormality determined to be not clinically significant by the Investigator; Grade 3 or 4 fever and chills; Grade 3 or 4 hypoalbuminemia or abnormal electrolytes that responded to supplementation/correction; AE related to the cancer or its progression.",
            "OutcomeMeasurePopulationDescription": "ITT Population. Treatment limiting toxicities were assessed in GSK3377794+pembrolizumab arm only.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 3 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline",
            "OutcomeMeasureDescription": "Blood samples were collected for the assessment of following clinical chemistry parameters: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, phosphate, sodium and calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population comprised of all participants in the ITT Population who received the NY-ESO-1c259T infusion.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Glucose (Hyperglycemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Glucose (Hypoglycemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Albumin (Hypoalbuminemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "ALP increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "ALT increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "AST increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Bilirubin increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Creatinine increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Potassium (Hyperkalemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Potassium (Hypokalemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Magnesium (Hypermagnesemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Magnesium (Hypomagnesemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Phosphate (Hypophosphatemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Sodium (Hypernatremia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Sodium (Hyponatremia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Calcium (Hypercalcemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Calcium (Hypocalcemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline",
            "OutcomeMeasureDescription": "Blood samples were collected for the assessment of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Hemoglobin (Anemia)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Hemoglobin increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Lymphocyte count decreased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Lymphocyte count increased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Neutrophil count decreased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Platelet count decreased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Leukocyte count decreased",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline",
            "OutcomeMeasureDescription": "Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population. Only those participants with data available at the specified time point is reported",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "1"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Prothrombin Time; decrease to low",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Prothrombin Time; To normal or no change",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Prothrombin Time; increase to high",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "PTT; decrease to low",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "PTT; To normal or no change",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "PTT; increase to high",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings",
            "OutcomeMeasureDescription": "ECG was recorded using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Overall Response Rate",
            "OutcomeMeasureDescription": "Overall response rate is defined as the percentage of participants with a best overall response (BOR) of confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) Response Criteria (2016); where, PR: >=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by >=90% or to <200 milligrams (mg) per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <= 5% plasma cells in bone marrow; or sCR: CR as defined by normal free light chain (FLC) ratio and absence of clonal cells by immunohistochemistry. Confidence intervals were calculated using the exact (Clopper-Pearson) method.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "Percentage of participants",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "33.3",
                              "OutcomeMeasurementLowerLimit": "0.8",
                              "OutcomeMeasurementUpperLimit": "90.6"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "66.7",
                              "OutcomeMeasurementLowerLimit": "9.4",
                              "OutcomeMeasurementUpperLimit": "99.2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Time to Response",
            "OutcomeMeasureDescription": "Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "Full Range",
            "OutcomeMeasureUnitOfMeasure": "Months",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "1"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "2"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0.7",
                              "OutcomeMeasurementLowerLimit": "NA",
                              "OutcomeMeasurementUpperLimit": "NA",
                              "OutcomeMeasurementComment": "Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual time to response for this single participant."
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0.7",
                              "OutcomeMeasurementLowerLimit": "0.7",
                              "OutcomeMeasurementUpperLimit": "0.7"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Duration of Response",
            "OutcomeMeasureDescription": "Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "Full Range",
            "OutcomeMeasureUnitOfMeasure": "Months",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "1"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "2"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2.1",
                              "OutcomeMeasurementLowerLimit": "NA",
                              "OutcomeMeasurementUpperLimit": "NA",
                              "OutcomeMeasurementComment": "Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual duration of response for this single participant."
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2.1",
                              "OutcomeMeasurementLowerLimit": "2.1",
                              "OutcomeMeasurementUpperLimit": "2.1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Progression-free Survival",
            "OutcomeMeasureDescription": "Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of >=0.5 grams per deciliter (g/dL); Serum M-protein increase >=1 g/dL if the lowest M-component was >=5 g/dL; Urinary M-protein (absolute increase must be >=200 mg per 24 hours).",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "Inter-Quartile Range",
            "OutcomeMeasureUnitOfMeasure": "Months",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2.79",
                              "OutcomeMeasurementLowerLimit": "1.31",
                              "OutcomeMeasurementUpperLimit": "5.16"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2.78",
                              "OutcomeMeasurementLowerLimit": "2.76",
                              "OutcomeMeasurementUpperLimit": "2.79"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Maximum Persistence (Cmax) of GSK3377794",
            "OutcomeMeasureDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Geometric Mean",
            "OutcomeMeasureDispersionType": "Geometric Coefficient of Variation",
            "OutcomeMeasureUnitOfMeasure": "Copies per microgram genomic DNA",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "38509.67",
                              "OutcomeMeasurementSpread": "160.5"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "89640.56",
                              "OutcomeMeasurementSpread": "84.8"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Time to Maximum Persistence",
            "OutcomeMeasureDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "Full Range",
            "OutcomeMeasureUnitOfMeasure": "Days",
            "OutcomeMeasureTimeFrame": "Up to 108 weeks",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8.0",
                              "OutcomeMeasurementLowerLimit": "5",
                              "OutcomeMeasurementUpperLimit": "15"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "8.0",
                              "OutcomeMeasurementLowerLimit": "7",
                              "OutcomeMeasurementUpperLimit": "15"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])",
            "OutcomeMeasureDescription": "Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.",
            "OutcomeMeasurePopulationDescription": "Modified ITT Population",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Geometric Mean",
            "OutcomeMeasureDispersionType": "Geometric Coefficient of Variation",
            "OutcomeMeasureUnitOfMeasure": "Days*Copies per microgram genomic DNA",
            "OutcomeMeasureTimeFrame": "Up to Day 28",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "GSK3377794",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "GSK3377794+Pembrolizumab",
                  "OutcomeGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "3"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "3"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "463989.35",
                              "OutcomeMeasurementSpread": "237.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1498869.21",
                              "OutcomeMeasurementSpread": "90.4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "5",
      "EventsTimeFrame": "Non-serious AEs and SAEs were collected up to 108 weeks.",
      "EventsDescription": "Non-serious AEs and SAEs were collected in the ITT Population. All-cause mortality was collected in the modified ITT Population.",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "GSK3377794",
            "EventGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.",
            "EventGroupDeathsNumAffected": "2",
            "EventGroupDeathsNumAtRisk": "3",
            "EventGroupSeriousNumAffected": "2",
            "EventGroupSeriousNumAtRisk": "3",
            "EventGroupOtherNumAffected": "3",
            "EventGroupOtherNumAtRisk": "3"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "GSK3377794+Pembrolizumab",
            "EventGroupDescription": "Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "3",
            "EventGroupSeriousNumAffected": "2",
            "EventGroupSeriousNumAtRisk": "3",
            "EventGroupOtherNumAffected": "3",
            "EventGroupOtherNumAtRisk": "3"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Pancytopenia",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Atrial flutter",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Bronchitis",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pneumonia",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Back pain",
            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Tumour pain",
            "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "SeriousEventSourceVocabulary": "MedDRA 24.0",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "3"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "3"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Anaemia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Thrombocytopenia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Leukopenia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Lymphopenia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neutropenia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fatigue",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Oedema peripheral",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pyrexia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chills",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Influenza like illness",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Mucosal inflammation",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Non-cardiac chest pain",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Diarrhoea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nausea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Constipation",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Stomatitis",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "White blood cell count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood lactate dehydrogenase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Lymphocyte count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neutrophil count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Platelet count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood albumin decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood alkaline phosphatase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood calcium increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood phosphorus decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood potassium decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood uric acid increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Amnesia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dizziness",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Headache",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypoaesthesia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Immune effector cell-associated neurotoxicity syndrome",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neuropathy peripheral",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Syncope",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Tremor",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Alopecia",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dermatitis acneiform",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pruritus",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash maculo-papular",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash pruritic",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin lesion",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Stasis dermatitis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cytokine release syndrome",
            "OtherEventOrganSystem": "Immune system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Graft versus host disease in skin",
            "OtherEventOrganSystem": "Immune system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Seasonal allergy",
            "OtherEventOrganSystem": "Immune system disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypocalcaemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypoalbuminaemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyponatraemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypophosphataemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Decreased appetite",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypercalcaemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperphosphataemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Arthralgia",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bone lesion",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bone pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flank pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Muscular weakness",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Atrial fibrillation",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Femur fracture",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rib fracture",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Wound",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash pustular",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper respiratory tract infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Plasmacytoma",
            "OtherEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Seborrhoeic keratosis",
            "OtherEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Insomnia",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Mental status changes",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Acute kidney injury",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cough",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dyspnoea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Epistaxis",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypoxia",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pleural effusion",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypertension",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypotension",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypothyroidism",
            "OtherEventOrganSystem": "Endocrine disorders",
            "OtherEventSourceVocabulary": "MedDRA 24.0",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "3"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "3"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "No",
        "AgreementRestrictionType": "OTHER",
        "AgreementRestrictiveAgreement": "Yes",
        "AgreementOtherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."
      },
      "PointOfContact": {
        "PointOfContactTitle": "GSK Response Center",
        "PointOfContactOrganization": "GlaxoSmithKline",
        "PointOfContactEMail": "GSKClinicalSupportHD@gsk.com",
        "PointOfContactPhone": "866-435-7343"
      }
    }
  },
  "DocumentSection": {
    "LargeDocumentModule": {
      "LargeDocList": {
        "LargeDoc": [
          {
            "LargeDocTypeAbbrev": "Prot",
            "LargeDocHasProtocol": "Yes",
            "LargeDocHasSAP": "No",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Study Protocol",
            "LargeDocDate": "February 24, 2020",
            "LargeDocUploadDate": "09/15/2021 03:57",
            "LargeDocFilename": "Prot_000.pdf"
          },
          {
            "LargeDocTypeAbbrev": "SAP",
            "LargeDocHasProtocol": "No",
            "LargeDocHasSAP": "Yes",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Statistical Analysis Plan",
            "LargeDocDate": "April 23, 2021",
            "LargeDocUploadDate": "09/15/2021 04:00",
            "LargeDocFilename": "SAP_001.pdf"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009101",
            "ConditionMeshTerm": "Multiple Myeloma"
          },
          {
            "ConditionMeshId": "D000054219",
            "ConditionMeshTerm": "Neoplasms, Plasma Cell"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000020141",
            "ConditionAncestorTerm": "Hemostatic Disorders"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000010265",
            "ConditionAncestorTerm": "Paraproteinemias"
          },
          {
            "ConditionAncestorId": "D000001796",
            "ConditionAncestorTerm": "Blood Protein Disorders"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000006474",
            "ConditionAncestorTerm": "Hemorrhagic Disorders"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11210",
            "ConditionBrowseLeafName": "Multiple Myeloma",
            "ConditionBrowseLeafAsFound": "Multiple Myeloma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26741",
            "ConditionBrowseLeafName": "Neoplasms, Plasma Cell",
            "ConditionBrowseLeafAsFound": "Multiple Myeloma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21130",
            "ConditionBrowseLeafName": "Hemostatic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4211",
            "ConditionBrowseLeafName": "Blood Coagulation Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12330",
            "ConditionBrowseLeafName": "Paraproteinemias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4229",
            "ConditionBrowseLeafName": "Blood Protein Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8712",
            "ConditionBrowseLeafName": "Hemorrhagic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3947",
            "ConditionBrowseLeafName": "Multiple Myeloma",
            "ConditionBrowseLeafAsFound": "Multiple Myeloma",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000003520",
            "InterventionMeshTerm": "Cyclophosphamide"
          },
          {
            "InterventionMeshId": "C000582435",
            "InterventionMeshTerm": "Pembrolizumab"
          },
          {
            "InterventionMeshId": "C000024352",
            "InterventionMeshTerm": "Fludarabine"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000018906",
            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
          },
          {
            "InterventionAncestorId": "D000000477",
            "InterventionAncestorTerm": "Alkylating Agents"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000019653",
            "InterventionAncestorTerm": "Myeloablative Agonists"
          },
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M289070",
            "InterventionBrowseLeafName": "Pembrolizumab",
            "InterventionBrowseLeafAsFound": "200",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafAsFound": "Months",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M283219",
            "InterventionBrowseLeafName": "Fludarabine",
            "InterventionBrowseLeafAsFound": "Medical",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M225481",
            "InterventionBrowseLeafName": "Fludarabine phosphate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20095",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2972",
            "InterventionBrowseLeafName": "Alkylating Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          }
        ]
      }
    }
  }
}